Orexo (ORX.ST) Osake Kurssi

Orexo AB is primarily active in the pharmaceutical industry.

The main competitors of Orexo AB in the market include pharmaceutical companies such as Indivior PLC, Mallinckrodt Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. These companies also operate in the field of addiction medicine and create products and treatments for substance abuse disorders.

Orexo AB is a pharmaceutical company headquartered in Sweden. Founded in 1995, Orexo has a rich history and background in developing innovative treatments for patients with opioid addiction. The company specializes in creating and commercializing unique medications using its proprietary technologies. With a focus on opioid dependence and pain management, Orexo has established itself as a leading player in the pharmaceutical industry. Orexo AB constantly strives to improve patient outcomes and contribute to the overall well-being of individuals dealing with addiction and pain-related issues.

Orexo AB has achieved several significant milestones since its establishment. The company successfully developed and commercialized Zubsolv®, a sublingual treatment for opioid dependence. Orexo AB also received approval for Abstral®, an innovative sublingual rapid-disintegrating tablet for cancer breakthrough pain management. Additionally, the company has secured partnerships and collaborations with multiple pharmaceutical companies, expanding its global reach and product portfolio. Orexo AB's dedication to research and development has led to the successful launch of pharmaceutical products that address unmet medical needs, reinforcing its position as a leading player in the pharmaceutical industry.

Orexo AB is primarily present in several countries and regions worldwide. The company has a significant presence in Europe, including countries like Sweden, Norway, Denmark, and Finland. Additionally, Orexo AB is expanding its footprint in the United States, where it is steadily growing its market presence. With its innovative pharmaceutical solutions and commitment to improving patient outcomes, Orexo AB is dedicated to reaching more regions and markets in the future.

Orexo AB represents values of innovation, integrity, and patient-centricity. As a pharmaceutical company, Orexo is dedicated to developing innovative solutions for the treatment of substance abuse and mental health disorders. The company's corporate philosophy revolves around improving the lives of patients by providing safe and effective medications. Orexo prioritizes ethical conduct, ensuring transparency and adhering to strict regulatory standards. Through its research and development efforts, Orexo aims to address unmet medical needs and make a positive impact on society. With its strong values and commitment to patient well-being, Orexo AB continues to be a trusted name in the pharmaceutical industry.

5 analyytikkoa arvioi tällä hetkellä Orexo-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Orexo-yhtiöltä 19,00 M SEK liikevaihtoa ja −9,76 SEK osakekohtaista tulosta.

Orexo Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Orexo-osake noteerataan hintaan 0,64 EUR (7,11 SEK).

Orexo-osake (ORX.ST) on listattuna 5 pörssissä, muun muassa: London (0H19.L), Frankfurt (C5G.F), Stockholm (ORX.ST).

Orexo AB is a pharmaceutical company focused on developing innovative medications for the treatment of opioid dependence, pain management, and other diseases. The company was founded in 1995 and is headquartered in Uppsala, Sweden. Orexo AB's business model is based on various divisions that allow the company to market its products at different levels. These divisions include medications for the treatment of opioid dependence, medications for pain management, benefit assessment and market access services, and research and development efforts. The company aims to provide tailored medications and services to meet the needs of patients and healthcare professionals. With its focus on opioid dependence and pain management, Orexo AB is well-positioned to serve a growing demographic and maintain high standards of product safety and quality. The company has a strong history of growth and continues to invest in research and development, making it a significant player in the market for opioid dependence and pain management.

odotettu liikevaihto Orexo on 19,00 M SEK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Orexo on −338,64 M SEK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Orexo:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,73. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Orexo-osakkeen arvostusta.

Orexo:n hinta-myynti-suhde (P/S) on tällä hetkellä 12,99. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Orexo-osakkeen arvostuskennuslukuna.

Orexo:n Eulpool-laatuscore on 1/10.

Orexo:n ISIN on SE0000736415. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Orexo:n WKN on A0HG6G. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Orexo:n ticker on ORX.ST. Tämä pörssinoteeraus käytetään Orexo-osakkeiden kauppaan pörssissä.